Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
February 04, 2021 07:30 ET
|
Corvus Pharmaceuticals, Inc.
Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory...
Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition
December 06, 2020 10:00 ET
|
Corvus Pharmaceuticals, Inc.
Updated interim data from CPI-818’s phase 1/1b clinical trial provide evidence supporting its potential as a treatment for T cell lymphomas New pre-clinical data provide evidence of CPI-818 ...
Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition
November 30, 2020 08:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company’s...
Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting
November 11, 2020 16:05 ET
|
Corvus Pharmaceuticals, Inc.
Data shows CPI-006 provided enhanced and prolonged polyclonal humoral immunity to SARS-CoV-2 Plans to initiate pivotal, randomized, double blind trial in December with results expected mid-2021 ...
Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 09, 2020 08:05 ET
|
Corvus Pharmaceuticals, Inc.
Data to be presented in a poster and an oral session “Hot Topic Symposium: COVID-19 and Cancer” at SITC Data shows CPI-006 provided enhanced and prolonged polyclonal humoral immunity to SARS-CoV-2 ...
Corvus Pharmaceuticals COVID-19 Abstract Selected for “Hot Topic” Oral Session at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 02, 2020 08:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its abstract covering updated data...
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
October 29, 2020 16:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced...
Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 29, 2020 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present updated data from...
Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China
October 05, 2020 07:24 ET
|
Corvus Pharmaceuticals, Inc.
Angel’s pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor program Strategic collaboration gives Corvus 49.7% equity...
New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19
October 05, 2020 07:22 ET
|
Corvus Pharmaceuticals, Inc.
Enrollment in first three cohorts complete; final cohort now enrolling with plans to initiate a pivotal study before year-end Data continues to support the novel immunotherapy based on B cell...